-
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
14 May 2024 20:05 GMT
… the manufacture of AAV-based genetic medicines.
Corporate Updates In alignment … leadership roles in Alector, Theravance, Affymax and CV Therapeutics (now Gilead … diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent …
-
OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights
09 Nov 2023 13:17 GMT
… Inc., Dialpad Inc., Mblox Inc., Affymax, Inc. and Connetics Corporation, among … ® and OmniMouse® that have been genetically modified to generate antibodies with …
-
OmniAb Appoints Steve Love to its Board of Directors
01 Nov 2023 13:42 GMT
… Inc., Dialpad Inc., Mblox Inc., Affymax, Inc. and Connetics Corporation, among … ® and OmniMouse® that have been genetically modified to generate antibodies with …
-
Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer
07 Nov 2022 22:00 GMT
… the lives of patients with genetically defined rare diseases, today announced … , Inc. (acquired by Pfizer), and Affymax (acquired by Glaxo Wellcome). Dr … the lives of patients with genetically defined rare diseases in areas …
-
Frontier Medicines Announces the Appointment of Seasoned Legal Executive Mark Dizon, J.D., as General Counsel
25 Aug 2022 16:14 GMT
… -- such as Chiron, Novartis, Affymax, Actelion, Relypsa and Prothena Biosciences … potentially develop groundbreaking medicines for genetically-defined patient populations, starting in …
-
BioSpace Movers & Shakers: Tessera, Tessa, Adial and More
26 Aug 2022 15:14 GMT
… its focus on rare and genetic diseases, oncology, and vaccines. Before … biotechs, such as Chiron, Novartis, Affymax, Actelion, Relypsa and Prothena Biosciences …
-
Goldfinch Bio Strengthens Leadership Team with Appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer
06 Dec 2021 13:00 GMT
… guidance for our biology and genetic research efforts as we aim … ultimately acquired by Pfizer) and Affymax/Glaxo-Wellcome, where he …
-
Opthea Appoints US-Based Non-Executive Director
10 Sep 2020 16:04 GMT
… Audit Committee Chair of Myriad Genetics, and the privately held companies … Seattle Genetics, Relypsa until its merger with Galenica AG, Anthera Pharmaceuticals, Affymax …
-
RubrYc Therapeutics Announces formation of its Scientific Advisory Board
05 Dec 2019 01:13 GMT
… a Research Unit Director at Affymax (1990 to 2000). Charles received … PhD in molecular biology and genetics from Yale University in 1987 …
-
Equillium Announces Leadership Updates
12 Nov 2019 21:07 GMT
… officer of Rincon Pharmaceuticals, a genetic engineering biotechnology company, until its … development and pharmacovigilance activities at Affymax where he was instrumental in … publications in the areas of genetics and renal disease. Christine Zedelmayer …